LIVN
LIVN
GB00BYMT0J19
LivaNova PLC
Loading chart...

Company Profile

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.

Latest News

Related stocks

SNN
SNN • United Kingdom
Smith & Nephew SNATS, Inc.
27.24 USD
11.4B USD 1Y -25%
SN.L
SN.L • United Kingdom
SMITH & NEPHEW PLC ORD USD0.20
1,020.5 GBp
11.3B USD 1Y -25.3%
SECT-B.ST
SECT-B.ST • Sweden
SECTRA AB ser B
310.2 SEK
5.98B USD 1Y -1.9%
GETI-B.ST
GETI-B.ST • Sweden
Getinge AB ser. B
253.2 SEK
6.9B USD 1Y +18%
MOVE.SW
MOVE.SW • Switzerland
MEDACTA GROUP N
114.2 CHF
2.74B USD 1Y -25.8%
EKTA-B.ST
EKTA-B.ST • Sweden
Elekta AB ser. B
54.45 SEK
2.08B USD 1Y +8%
DRW3.DE
DRW3.DE • Germany
DRAEGERWERK VZO O.N.
116.6 EUR
2.45B USD 1Y +70.6%
NVCR
NVCR • Switzerland
NovoCure Limited
14.58 USD
1.7B USD 1Y -0.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
39.6% p.a.
Max Drawdown (5Y)
-63.5%
Sharpe Ratio (5Y)
-0.08
Beta Factor
0.88
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (39.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -74.2% in the extended horizon.
ende